Gilead's remdesivir effective against multiple COVID variants, including Omicron
Bill Oxford/iStock via Getty Images


New data released by Gilead Sciences (NASDAQ:GILD) indicates that its COVID-19 treatment Veklury (remdesivir) is effective against 10 variants, including Omicron.
Results from Gilead studies corroborate what has been found in other in vitro studies conducted by researchers around the world.

The company's study showed that Veklury had a similar neutralizing effect against the variants.
Results, which have yet to be peer reviewed, were published as a preprint in bioRxiv.
Check out why Seeking Alpha contributor The Value Investor considers Gilead a hold.